JPMorgan 24th Annual Healthcare Conference -- interviews with Amicus Therapeutics Inc and Portola Pharmaceuticals Inc.
Dalziel
Chris
C
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. christopher.dalziel@thomson.com
D002986:Clinical Trials as Topic; D003695:Delivery of Health Care; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D000795:Fabry Disease / Q000188:drug therapy; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use; D005776:Gaucher Disease / Q000188:drug therapy; D006801:Humans; D018832:Molecular Chaperones / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy; D020246:Venous Thrombosis / Q000188:drug therapy; D000519:alpha-Galactosidase / Q000627:therapeutic use
D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D018832:Molecular Chaperones; D000519:alpha-Galactosidase